Tarsus Pharmaceuticals Inc (TARS)

$69.88 -3.14 (-4.30%)
Market Cap 3.17B
Revenue (ttm) 451.36M
Net Income (ttm) -66.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.72%
Debt to Equity Ratio 0.21
Volume 696,500
Avg Vol 637,222
Day's Range N/A - N/A
Shares Out 42.56M
Stochastic %K 20%
Beta 0.55
Analysts Strong Sell
Price Target $91.12

Company Profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-0...

Industry: Biotechnology
Sector: Healthcare
Phone: (949) 418-1801
Address:
15440 Laguna Canyon Road, Suite 160, Irvine, United States
NYTWben
NYTWben Mar. 10 at 2:29 PM
$LENZ Listening to the Leerink fireside chat now. The CEOis literally talking about the business plan right now. Nod to short here NICO who always says no business plan. He is comparing the phased launch to $TARS (I also own TARSUS). $TARS is a doing great.
3 · Reply
Magnificient
Magnificient Mar. 3 at 8:40 AM
$TARS Hmm this or $TGTX or $VKTX
2 · Reply
sunset_PARK
sunset_PARK Mar. 2 at 8:52 PM
$CPRX $KNSA $TARS they all moved last 30mins withvolume, similar market cap in bio, any news, any others? Seems not in the same index?
1 · Reply
RonIsWrong
RonIsWrong Mar. 2 at 8:37 PM
$TARS TARS will just keep sneaking up while no one is looking
1 · Reply
Tmoney85285
Tmoney85285 Feb. 26 at 3:33 PM
$TARS $OCUL reading is not his strong suit- now you can short OCUL though. thank me later.
1 · Reply
Count_Von_Count
Count_Von_Count Feb. 26 at 1:45 PM
$TARS
0 · Reply
InvestorNOR
InvestorNOR Feb. 25 at 5:02 PM
$TARS $OCUL This is the clown that told everyone to short Ocular at $6.5 🤣🤣🤣🤣🤣
0 · Reply
jpcalm68
jpcalm68 Feb. 25 at 3:24 PM
$BBIO $TARS $HNGE 3 Bio tech companies with bright futures.
0 · Reply
erevnon
erevnon Feb. 25 at 2:59 PM
Guggenheim maintains Tarsus Pharmaceuticals $TARS at Buy and raises the price target from $87 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
CH_Expat
CH_Expat Feb. 24 at 7:57 PM
$TARS Glad for you longs though.
0 · Reply
Latest News on TARS
Tarsus to Participate in Upcoming Investor Conferences

Feb 26, 2026, 4:30 PM EST - 13 days ago

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential

Feb 24, 2026, 1:47 PM EST - 15 days ago

Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 6:15 AM EST - 15 days ago

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

Feb 18, 2026, 8:30 AM EST - 21 days ago

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

Feb 17, 2026, 4:30 PM EST - 22 days ago

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

Allspring Emerging Growth Fund Q4 2025 Performance Review

Feb 4, 2026, 2:24 PM EST - 5 weeks ago

Allspring Emerging Growth Fund Q4 2025 Performance Review

AMSC ATI CORT CRS CSTL CVLT CWAN

Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3

Nov 20, 2025, 1:46 PM EST - 3 months ago

Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 10:56 PM EST - 4 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Nov 4, 2025, 4:05 PM EST - 4 months ago

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 28, 2025, 5:00 PM EDT - 4 months ago

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off

Sep 26, 2025, 1:05 PM EDT - 5 months ago

Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off

Top 2 Health Care Stocks That May Fall Off A Cliff In August

Aug 20, 2025, 8:46 AM EDT - 7 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff In August

PINC

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 3:04 AM EDT - 7 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 30, 2025, 5:00 PM EDT - 8 months ago

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off

May 12, 2025, 12:28 PM EDT - 10 months ago

Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

May 5, 2025, 6:27 AM EDT - 11 months ago

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

ELAN

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:37 PM EDT - 11 months ago

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript

Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

May 1, 2025, 4:05 PM EDT - 11 months ago

Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Apr 24, 2025, 5:00 PM EDT - 11 months ago

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

Apr 22, 2025, 8:31 AM EDT - 11 months ago

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

Mar 12, 2025, 9:49 PM EDT - 1 year ago

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

Tarsus Announces Proposed $100.0 Million Public Offering

Mar 12, 2025, 4:12 PM EDT - 1 year ago

Tarsus Announces Proposed $100.0 Million Public Offering

Tarsus Pharma: Strong Execution In Xdemvy Commercialization

Mar 11, 2025, 12:36 PM EDT - 1 year ago

Tarsus Pharma: Strong Execution In Xdemvy Commercialization

Tarsus to Participate in Upcoming Investor Conference

Mar 6, 2025, 5:00 PM EST - 1 year ago

Tarsus to Participate in Upcoming Investor Conference

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 6:01 PM EST - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Feb 20, 2025, 5:00 PM EST - 1 year ago

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Jan 13, 2025, 8:30 AM EST - 1 year ago

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Dec 15, 2024, 2:00 PM EST - 1 year ago

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

SWTX

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 10:23 PM EST - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Nov 13, 2024, 8:30 AM EST - 1 year ago

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

Nov 5, 2024, 8:30 AM EST - 1 year ago

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

Sep 25, 2024, 5:00 PM EDT - 1 year ago

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations

Sep 20, 2024, 3:17 PM EDT - 1 year ago

Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

Aug 28, 2024, 5:00 PM EDT - 1 year ago

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment

Aug 20, 2024, 4:56 PM EDT - 1 year ago

Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:50 PM EDT - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 29, 2024, 4:30 PM EDT - 1 year ago

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

May 9, 2024, 5:00 PM EDT - 1 year ago

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript

May 8, 2024, 9:45 PM EDT - 1 year ago

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

May 8, 2024, 4:05 PM EDT - 2 years ago

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

May 1, 2024, 5:00 PM EDT - 2 years ago

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

Apr 23, 2024, 8:30 AM EDT - 2 years ago

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Mar 7, 2024, 8:03 PM EST - 2 years ago

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Tarsus to Participate at Upcoming Investor Conferences

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tarsus to Participate at Upcoming Investor Conferences

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Mar 5, 2024, 8:30 AM EST - 2 years ago

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Tarsus Announces Pricing of $100.0 Million Public Offering

Mar 1, 2024, 12:07 AM EST - 2 years ago

Tarsus Announces Pricing of $100.0 Million Public Offering

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 12:09 PM EST - 2 years ago

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript

NYTWben
NYTWben Mar. 10 at 2:29 PM
$LENZ Listening to the Leerink fireside chat now. The CEOis literally talking about the business plan right now. Nod to short here NICO who always says no business plan. He is comparing the phased launch to $TARS (I also own TARSUS). $TARS is a doing great.
3 · Reply
Magnificient
Magnificient Mar. 3 at 8:40 AM
$TARS Hmm this or $TGTX or $VKTX
2 · Reply
sunset_PARK
sunset_PARK Mar. 2 at 8:52 PM
$CPRX $KNSA $TARS they all moved last 30mins withvolume, similar market cap in bio, any news, any others? Seems not in the same index?
1 · Reply
RonIsWrong
RonIsWrong Mar. 2 at 8:37 PM
$TARS TARS will just keep sneaking up while no one is looking
1 · Reply
Tmoney85285
Tmoney85285 Feb. 26 at 3:33 PM
$TARS $OCUL reading is not his strong suit- now you can short OCUL though. thank me later.
1 · Reply
Count_Von_Count
Count_Von_Count Feb. 26 at 1:45 PM
$TARS
0 · Reply
InvestorNOR
InvestorNOR Feb. 25 at 5:02 PM
$TARS $OCUL This is the clown that told everyone to short Ocular at $6.5 🤣🤣🤣🤣🤣
0 · Reply
jpcalm68
jpcalm68 Feb. 25 at 3:24 PM
$BBIO $TARS $HNGE 3 Bio tech companies with bright futures.
0 · Reply
erevnon
erevnon Feb. 25 at 2:59 PM
Guggenheim maintains Tarsus Pharmaceuticals $TARS at Buy and raises the price target from $87 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
CH_Expat
CH_Expat Feb. 24 at 7:57 PM
$TARS Glad for you longs though.
0 · Reply
Tmoney85285
Tmoney85285 Feb. 24 at 7:22 PM
$TARS opened a starter position today- will add if there are dips.
1 · Reply
Hawksssss
Hawksssss Feb. 24 at 2:32 PM
$TARS very
0 · Reply
TickrTalk0007
TickrTalk0007 Feb. 24 at 2:32 PM
$TARS Looks like the company is front running and stuffing channels.... if you draw 2 Lines one for SG&A and sales....surprisingly they will coincide with correlation coefficient R2 of 0.9
1 · Reply
TickrTalk0007
TickrTalk0007 Feb. 24 at 2:22 PM
$TARS spend $430M to make $450M
1 · Reply
ortega1963
ortega1963 Feb. 24 at 11:34 AM
$TARS Next stopp 85 $
1 · Reply
ortega1963
ortega1963 Feb. 24 at 6:38 AM
$TARS Nice Chart
0 · Reply
Biotechace
Biotechace Feb. 24 at 3:59 AM
$TARS I hope they don't sell out to soon. Let this thing ride for a few more years so we can actually see the full potential of the share price.
1 · Reply
Biotechace
Biotechace Feb. 24 at 3:40 AM
$TARS 2 billion x 5.5 revenues = $11 billion ÷ 43 million shares = $255 per share
1 · Reply
6GodEnergy
6GodEnergy Feb. 24 at 1:03 AM
1 @SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $ETSY $RNG $TARS $COKE * on watch as well.
0 · Reply
Hawksssss
Hawksssss Feb. 24 at 12:07 AM
$TARS 28% q on q growth. Impressive
0 · Reply
6GodEnergy
6GodEnergy Feb. 23 at 11:41 PM
^@SqueezeSharkie on a different level better than 90% of the traders on this platform. Focused, intentional, real game shared. If you’re not tuned in, that’s a miss, make sure to follow him! $VVPR $ALOY $BEX $TARS < on watch
0 · Reply
Blazed_Beast
Blazed_Beast Feb. 23 at 11:00 PM
$TARS Great call! Exciting outlook for sure!
0 · Reply